Cardiff Oncology Profit Margin 2006-2021 | CRDF
Current and historical gross margin, operating margin and net profit margin for Cardiff Oncology (CRDF) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Cardiff Oncology net profit margin as of June 30, 2021 is -5830.38%.
|Cardiff Oncology Annual Profit Margins
|Cardiff Oncology Quarterly Profit Margins
||Medical - Biomedical and Genetics
Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of onvansertib in combination with Zytiga(R) in Zytiga-resistant metastatic castration-resistant prostate cancer; and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Cardiff Oncology Inc., formerly known as Trovagene Inc., is based in SAN DIEGO.